JP2019099497A - Composition for improving liver function - Google Patents

Abstract

To provide compositions for improving liver function.SOLUTION: Provided is a composition for improving liver function, comprising arginine, alanine, and phenylalanine as active ingredients, the total number of moles of arginine, alanine and phenylalanine being 60 moles or more when the total number of moles of all amino acids in the composition is 100 moles.SELECTED DRAWING: None

Description

  The present invention relates to a composition for improving liver function, and a food and drink containing the composition.

  Obesity is a risk factor that causes metabolic syndrome and insulin resistance and increases the morbidity or mortality of hypertension, diabetes, cardiovascular disease, and cancer (Non-patent Document 1). Intervention techniques for weight loss include diet and exercise interventions and combinations of these, and such weight loss interventions result in decreased weight and body fat percentage, including blood pressure, serum lipids, blood glucose, and liver function. It is reported that it improves (a nonpatent literature 2-4).

  There are already many reports on the liver function improvement effect by exercise intervention, for example, reports that the liver function improvement effect correlates with the weight loss effect (Non-patent documents 5 and 6), and liver fat is independent of weight loss. There is also a report (Non-Patent Document 7) that it is said to decrease.

  Many reports have also been made on the liver function improving effect of food materials, and in particular, research on amino acids whose main metabolic organ is the liver has attracted attention. As amino acids that promote ethanol metabolism in the liver, alanine (Non-patent Document 8), glutamine and asparagine (Non-patent document 9), cysteine (Non-patent document 10), glycine and serine (Non-patent document 11) are reported. ing. Also, asparagine (Non-patent Document 12) has been reported as an amino acid that promotes lipid metabolism in the liver. In addition, amino acids that may improve liver function decline due to alcohol excess intake include alanine (Non-patent document 13), arginine (Non-patent document 14), cysteine (Non-patent documents 15 and 16), methionine and tryptophan ( Non Patent Literature 17) has been reported. However, they are all reported in a model of drug administration in animals or in an evaluation system in high dose administration to animals, and are actually targeted at obese humans and given to the liver when amino acids are ingested for a long time in combination with exercise. There have been no reports of studies that evaluated the impact. Although there has been a report of transfusion administration of BCAA to human patients with hepatic encephalopathy (Non-patent Document 18), the dose is extremely high level of 150 g / day, and amino acids are used as meal substitutes as they are ing.

  On the other hand, various research results have been reported for amino acid compositions that perform well in addition to liver function improvement effects. For example, as a composition for transfusion having lipid and carbohydrate metabolism regulating activity, a composition comprising threonine, proline, glycine, valine, isoleucine, leucine, leucine, tyrosine, phenylalanine, lysine, methionine, tryptophan, histidine, and arginine as main components Have been reported (Patent Document 1). In addition, at least one amino acid having a glucagon secretion promoting action, at least one xanthine derivative, at least one isoflavone, and at least one carnitine or carnitine precursor as a substance for preventing, ameliorating or treating the metabolic syndrome A composition containing one type has been reported (Patent Document 2).

  In addition, a mixture containing arginine, alanine and phenylalanine in a mass ratio of 1: 1: 2 has been developed, and it has been reported that 3 g of the mixture before exercise promotes fat burning during and after exercise. (Non-Patent Document 19).

Unexamined-Japanese-Patent No. 1994-024976 JP 2008-291002 A

Hu FB. Obesity Epidemiology. Oxford University Press, New York, 2008 Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord. 1997; 21: 941-7 Nakata Y, Okura T, Matsuo T, Tanaka K. Factors alleviating metabolic syndrome via diet-induced weight loss with or without exercise in over-weight Japanese women. Prev Med. 2009; 48: 351-6 Norris SL, Zhang X, Avenell A, et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med. 2004; 117: 762-74 Exercise reducing inflammation and oxidative stress in obesity-related liver diseases. Medicine & Science in Sports & Exercise, 2013; 45; 2214-2222. Sechang Oh, Kiyoji Tanaka, Eiji Warabi, Junichi Shoda. Sechang Oh, Kiyoji Tanaka, Takehiko Tsujimoto, Rina So, Takahashi Shida, Junichi Shoda, Regular Exercise Coupled to Dietary Acceleration Reduction of Hepatic Conditions and Associated Pathological Conditions in Non-Alcoholic Fatty Liver Diseases 290-298. Moderate to Vigorous Physical Activity Volume and Managing Factors for Managing Non-Alcoholic Fatty Liver Disease: A Retrospective Study [in Japanese] chang chang chang, Shi d masa, iyo Ta, ina hiko, T Mawatari Kazunori. Arai Hiromitsu. Alanine and glutamine improve liver damage. Food Style 21. 6 (11): 48-52 2002. Efthivoulou MA, Phillips JW, Berry MN. Abolition of the inhibitory effect of ethanol oxidation on gluconeogenesis from lactate by asparagine or low concentrations of ammonia. Biochim Biophys Acta. 1995 Jun 9; 1244 (2-3): 303-10. Tsukamoto S, Kanegae T, Nagoya T, Shimamura M, Mieda Y, Nomura M, Hojo K, Okubo H. Effects of amino acids on acute alcohol in toxication in mice-concentrations of ethanol, acetaldehyde, acetate and acetone in blood and tissue. Arukoru Kenkyuto Yakubutsu Ison. 1990 Oct; 25 (5): 429-40. Reduction of acute alcoholic intoxication by alpha amino acids: glycine and serum. Life Sci. 1974 Feb 1; 14 (3): 557-65. Alexander NM, Scheig R, Klatskin G. Effects of L-asparagine and related compounds on the hepatic fatty infiltration and necrosis induced by ethionine and carbon tetrachloride. Biochem Pharmacol. 1967 Jun; 16 (6): 1009 1-7. Maezono K, Kajiwara K, Mawatari K, Shinkai A, Torii K, Maki T. Alanine protects liver from injury caused by F-galactosamine and CCl4. Hepatology. 1996 Jul; 24 (1): 185-91. Adawi D, Kasravi FB, Molin G, Jeppsson B. Oral arginine supplementation in acute liver injury. Nutrition. 1996 Jul-Aug; 12 (7-8): 529-33. de Ferreyra EC, de Fenos OM, Bernacchi AS, de Castro CR, Castro JA. Therapeutic effectiveness of cysteamine and cysteine to reduce liver cells Necrosis induced by several hepatotoxins. Toxicol Appl Pharmacol. 1979 Apr; 48 (2): 221-8. Macdonald CM, Dow J, Moore MR. A possible protective role for sulphydryl compounds in acute alcoholic liver Injury. Biochem Pharmacol. 1977 Aug 15; 26 (16): 1529-31. Kroeger H, Graetz R, Museteanu C, Haase J. Influence of nicotinic acid amide, tryptophan, and methionine upon galactosamine-induced hepatitis. Naturwissenschaften. 1979 Sep; 66 (9): 476-7. Masuzawa M1, Okuyama T, Kato M. Parenteral and enteral nutritional support for patients with liver cirrhosis. Nihon Rinsho. 1994 Jan; 52 (1): 203-8. Ueda K, Sanbongi C, Takai S, Ikegami S, Fujita S. Combination of aerobic exercise and an arginine, alanine, and phenylalanine mixture increase in fate body and body body synthesis. Biosci Biotechnol Biochem. 2017 Jul; 81 (7): 17 (7) 1424.

  The present inventors took the placebo composition by causing the subject to continuously perform low-intensity exercise and continuously taking a composition containing high concentrations of arginine, phenylalanine and alanine. It has been found that blood parameters that are indicators of liver function such as AST (aspartate aminotransferase), ALP (alkaline phosphatase), γ-GTP (γ-glutamyl transpeptidase) and the like are significantly reduced in comparison with subjects, It has been found that the composition improves liver function. The present invention is based on this finding.

  Therefore, an object of the present invention is to provide a composition for improving liver function and a food or drink containing the composition.

According to the present invention, the following inventions are provided.
(1) A composition for improving liver function, comprising arginine, alanine and phenylalanine as active ingredients, wherein arginine, alanine and alanine and the total number of moles of all amino acids in the composition are 100 moles. The composition, wherein the total number of moles of phenylalanine is 60 moles or more.
(2) The composition according to (1), wherein the molar ratio of arginine, alanine and phenylalanine is 5.0 to 90.0: 5.0 to 90.0: 5.0 to 90.0.
(3) The composition according to (2), wherein the molar ratio of arginine, alanine and phenylalanine is 10.0 to 30.0: 20.0 to 60.0: 10.0 to 70.0.
(4) The composition according to any one of (1) to (3), wherein the total number of moles of arginine, alanine and phenylalanine is 90 to 100 moles when the total number of moles of all amino acids is 100 moles. object.
(5) The composition according to any one of (1) to (4), for reducing at least one blood parameter selected from AST, ALP and γ-GTP.
(6) Food / beverage products which contain the composition in any one of (1)-(5).
(7) The food or drink according to (6), which is any one form selected from the group consisting of a beverage, granules, powder and liquid food.

  The composition for improving liver function of the present invention can promote blood pressure drop in a subject whose liver function is to be improved. In particular, the composition of the present invention can significantly improve liver function of a subject with high blood pressure such as an obese person, when trying to improve liver function by weight loss by exercise. In addition, the improvement of liver function by the composition of the present invention is particularly advantageous in that it is remarkable not only by intense exercise but also by the combination of low intensity and light exercise (physical activity). Furthermore, the composition of the present invention is also advantageous in that it exerts a liver function improving effect at a low dose (for example, 1.5 g / day).

FIG. 1 is a graph showing changes in AST at the start of the test (Week 0) in Example 2 and at 4, 8 and 12 weeks after the start of the test. FIG. 2 is a graph showing changes in ALP at the start of the test (Week 0) and at 4, 8, and 12 weeks after the start of the test in Example 2. FIG. 3 is a graph showing changes in γ-GTP at the start of the test (Week 0) and at 4, 8, and 12 weeks after the start of the test in Example 2.

Detailed Description of the Invention

  Hereinafter, the present invention will be described in detail. However, the present invention is not limited to the following preferred embodiments, and can be freely changed within the range in which the effects of the present invention are exhibited.

  The composition for promoting blood pressure drop of the present invention (also referred to herein as "the composition of the present invention") contains arginine, alanine and phenylalanine as active ingredients.

  Arginine is one of non-essential amino acids, and D-form and L-form exist. L-Arginine Cas No. 74-79-3, (S) -2-amino-5-guanidinopentanoic acid, (S) -2-amino-5- (amidinoamino) valeric acid, L-(+)-arginine or Algi U It is sometimes called. In some cases, "Arg" or "R" is used as an abbreviation of arginine. Arginine is soluble in water and formic acid, soluble in dilute hydrochloric acid, and practically insoluble in ethanol (the 16th revised Japanese Pharmacopoeia). Arginine is known to be contained in various materials and foods such as various proteins such as meats. Arginine is biosynthesized as an intermediate of the urea cycle, but it is regarded as an essential amino acid in children because it is rapidly degraded. Arginine is known to be involved in promoting growth hormone secretion and improving immune function.

Alanine (Alanine) is one of non-essential amino acids, and D-form and L-form exist. L-alanine Cas No. Is 56-41-7 and may also be referred to as (S) -2-aminopropionic acid, (2S) -2-aminopropanoic acid, α-alanine or L-(+)-alanine. In some cases, “Ala” or “A” is used as an abbreviation of alanine.
Alanine is readily soluble in water and formic acid, and practically insoluble in ethanol (16th Amended Japanese Pharmacopoeia). Alanine is known to be contained in various materials and foods such as various proteins such as meats. Alanine is one of the constituent amino acids of proteins and is known to be a material of connective tissue.

  Phenylalanine (Phenylalanine) is one of the essential amino acids, and D-form and L-form exist. L-Phenylalanine Cas No. Is 63-91-2, (S)-. Alpha.-aminobenzenepropanoic acid, (2S) -2-amino-3-phenylpropanoic acid, (S) -3-phenyl-2-aminopropionic acid, L- It may also be referred to as β-phenylalanine or L-(-)-phenylalanine. As an abbreviation of phenylalanine, "Phe" or "F" may be used. Phenylalanine is easily soluble in formic acid, slightly soluble in water, soluble in dilute hydrochloric acid, and practically insoluble in ethanol (16th revised Japanese Pharmacopoeia). It is known that phenylalanine is contained in various materials and foods such as various proteins such as meats.

  The content of arginine, alanine and phenylalanine in the composition of the present invention is 60 moles or more and 70 moles or more when the total number of moles of all the amino acids contained in the composition is 100 moles. The amount is preferably 80 mol or more, more preferably 90 mol or more, and particularly preferably 100 mol.

  Further, the molar ratio of arginine, alanine and phenylalanine (arginine: alanine: phenylalanine) contained in the composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired. It is preferable that it is 5.0 to 90.0: 5.0 to 90.0, and more preferably 5.0 to 50.0: 5.0 to 50.0: 5.0 to 80.0. More preferably, it is 10.0 to 30.0: 20.0 to 60.0: 10.0 to 70.0, and 19.5 to 20.4: 37.5 to 38.4: 41.5. It is even more preferable that it is ~ 42.4, and it is particularly preferable that it is 20: 38: 42.

  The blending amounts of arginine, alanine and phenylalanine in the composition of the present invention can be appropriately determined according to the form of the composition, the age, weight and condition of the subject taking the composition, the use and the like. The blending amounts of arginine, alanine and phenylalanine in the composition of the present invention are not particularly limited as long as the effects of the present invention are not impaired, but the total amount of arginine, alanine and phenylalanine relative to the composition is 0.2 to 100% by weight Is preferable, 0.3 to 100% by weight is more preferable, and 0.4 to 100% by weight is particularly preferable.

  Arginine, phenylalanine and alanine contained in the composition of the present invention may be either D-form or L-form.

  Since arginine, alanine and phenylalanine are suitable for eating and drinking and oral intake, the composition of the present invention containing these at high concentration is excellent in flavor. Therefore, the composition of the present invention has the advantage of not impairing the taste of food or drink or pharmaceutical preparation to which it is added.

  The composition of the present invention may further contain other amino acids besides arginine, phenylalanine and alanine. Other amino acids are not particularly limited as long as the effect of the present invention is not impaired, but glycine, proline, lysine, tyrosine, threonine, leucine, valine, isoleucine, glutamic acid, tryptophan, histidine, serine, methionine and aspartic acid etc. It can be mentioned. Any other amino acid may be contained in the composition of the present invention, or two or more may be contained in combination.

When the composition of the present invention further contains other amino acids, the content of the other amino acids is not particularly limited as long as the effects of the present invention are not impaired, but the total number of moles of all amino acids contained in the composition Of one amino acid or two or more of the other amino acids, respectively. Glycine 0.01 to 4 moles Proline 0.01 to 4 moles Lysine 0.01 to 2 moles Tyrosine 0.01 to 2 moles Threonine 0 0.01 to 2 moles leucine 0.01 to 2 moles valine 0.01 to 2 moles isoleucine 0.01 to 2 moles glutamic acid 0.01 to 1 mole tryptophan 0.01 to 1 mole histidine 0.01 to 1 mole serine 0. It is preferable to contain it in the quantity of 0.01-1 mole of methionine 0.01-0.2 mole aspartic acid 0.01-0.1 mole.

  All of arginine, phenylalanine, alanine and other amino acids contained in the composition of the present invention may be in the form of free base, and may be in the form of hydrate or salt. The salt is not particularly limited as long as the effects of the present invention are not impaired, but, for example, organic acids (acetic acid, tartaric acid, fatty acids, etc.), organic bases, inorganic acids (hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, perchlorine And salts with inorganic bases (such as potassium, sodium and zinc).

  Furthermore, arginine, phenylalanine, alanine and other amino acids contained in the composition of the present invention can be prepared from materials, foods and the like containing those amino acids using known methods such as squeezing, concentration, purification, crystallization and extraction. It can be obtained by using. Furthermore, it is also possible to use one produced using a microorganism or one synthesized chemically. The solvent used for the extraction from the raw material and the food is not particularly limited as long as the effect of the present invention is not impaired, but, for example, water, alcohols, hydrocarbons, organic acids, organic bases, organic acids, inorganic acids, inorganic substances Solvents commonly used for extraction, such as bases and supercritical fluids, may be mentioned. One of these solvents may be used alone, or two or more thereof may be used in combination.

  In addition, the composition of the present invention may be further formulated, if desired, using pharmaceutically acceptable additives, and such an embodiment is also encompassed by the present invention. The pharmaceutically acceptable additive is not particularly limited as long as the effects of the present invention are not impaired, and, for example, excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspensions Agents, coatings, solvents, tonicity agents, and the like. Moreover, as an agent containing the composition of this invention, the thing of dosage forms, such as a tablet (tablet), a capsule, a granule, a powder, a syrup, a solution, and a suspension agent, is mentioned, for example. Furthermore, these agents may be blended with appropriate amounts of vitamins, minerals, organic acids, saccharides, peptides and / or amino acids not listed above, etc., as long as the effects of the present invention are not impaired. . In addition, these agents can be taken or administered by routes such as oral, tube and vein.

  In addition, the composition of the present invention can be in various forms without particular limitation as long as the effects of the present invention are not impaired, and can be suitably taken orally. Specifically, the composition of the present invention can be in the form of a solid, such as powder or granules, a paste, a gel, a liquid, or a suspension.

  According to the present invention, there are provided a medicine, a food and drink, a nutritional composition, a supplement and the like containing the composition of the present invention. Among these, food and drink containing the composition of the present invention are preferable, and as food and drink, for example, special purpose food, nutritive functional food, nutraceutical food, health food, pharmaceutical additive, food for specified health use and Functional indication food etc. are mentioned. More specifically, various foods (milk, soft drink, fermented milk, yogurt, cheese, bread, biscuit, cracker, pizza crust, prepared milk powder, liquid food, sick food, nutritional food, frozen food, processed food) And other commercially available foods). In the present specification, "containing" the composition of the present invention includes the meaning of "including" and "as a raw material" of the composition of the present invention.

  Water, proteins, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like can be blended into food and drink products containing the composition of the present invention. Examples of proteins include whole milk powder, skimmed milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, whey protein hydrolyzate, α-casein, β-casein, κ -Animal and vegetable proteins such as casein, β-lactoglobulin, α-lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein, etc., their decomposition products, butter, whey mineral, cream, whey, non-protein nitrogen, sialic Examples include various milk-derived components such as acids, phospholipids and lactose. It may contain a peptide such as casein phosphopeptide or an amino acid. Examples of the sugar include saccharides, modified starch (in addition to texturin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber and the like. Examples of lipids include lard, fish oil, etc., animal fats and oils such as fractionated oil, hydrogenated oil, transesterified oil, palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, etc. Vegetable fats and oils such as fractionated oil, hydrogenated oil, transesterified oil, etc. may be mentioned. As vitamins, for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline And folic acid. As minerals, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium etc. are mentioned, for example. Examples of the organic acid include malic acid, citric acid, lactic acid, tartaric acid, erythorbic acid and the like. These ingredients may be used alone or in combination of two or more kinds, and synthetic products and / or foods containing a large amount of these may be used. The form of these foods may be liquid, paste, gel, solid, powder or the like.

  The daily intake of the composition of the present invention can be appropriately determined according to the content of the active ingredient in the composition, the age, weight and condition of the subject taking the composition, the use, and the like. The daily intake of the composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, but the total amount of amino acids contained in the composition is, for example, 0.3 to 30 g as solid content. The intake can be preferably 0.8 to 8 g, more preferably 1 to 5 g, 1.3 to 3.5 g, and further preferably 1.5 g or 3 g.

  In addition, the composition of the present invention may be taken simultaneously with a conventionally known food and drink, medicine and the like having a liver function improving effect, or may be taken before and after the intake thereof.

  In the present invention, the use of arginine, alanine and phenylalanine for producing a composition for improving liver function (method of use), wherein the total number of moles of all amino acids in the composition is 100 moles. Also included is the use wherein the total number of moles of arginine, alanine and phenylalanine is 60 moles or more.

  Furthermore, the present invention also encompasses a method of promoting blood pressure reduction in a subject, comprising administering the composition of the present invention to the subject.

  The subject receiving the composition of the present invention may be any person, regardless of the need to improve liver function, but in view of the liver function improving action of the composition, Can be thought of as those who want to improve liver function. Thus, subjects include not only those whose physicians indicate liver dysfunction, but also healthy individuals who want to improve liver function. Also, in the following examples, it is demonstrated that the improvement of liver function by adding light exercise (increasing the number of steps per day by 1000 steps) is promoted by the intake of the composition of the present invention. However, since daily exercise before adding light exercise varies from person to person, it is not necessary to condition addition of daily exercise when taking the composition of the present invention, and each subject in each subject It is thought that the improvement effect of liver function can be obtained according to the amount of exercise. On the other hand, since the liver function improving effect of the composition of the present invention is enhanced by increasing the amount of exercise, the present invention is applied to a subject whose exercise amount per day is increased more than before to improve liver function. Ingestion of the composition of (1) is a preferred embodiment of the present invention.

  EXAMPLES Hereinafter, the present invention will be more specifically described by way of examples, but the present invention is not limited by these examples.

Example 1: Preparation of a composition of the present invention The molar ratio of arginine, alanine and phenylalanine is 20:38: 42 (total of moles of arginine, alanine and phenylalanine when total amount of moles of all amino acids is 100 moles) The mixture was made into a composition of the present invention (hereinafter also referred to as "A-mix").

Example 2: Examination of the blood pressure drop promoting effect of the composition of the present invention In this example, a combination of continuous intake of the composition (A-mix) of the present invention and enlightenment of increase in physical activity is the liver function of obese people The clinical trial was conducted for 200 people, with the issue of whether it was possible to improve In enlightenment of physical activity increase, intake of A-mix containing drink (1.5 g / day) with intervention of "let's increase 1000 steps a day, increase step number" recommended by health Japan 21 of Ministry of Health, Labor and Welfare The effects of using for 12 weeks were evaluated. The details of the specific test were as follows.

Subjects of subjects 20 to 64 years old who were obese I (BMI 25 or more and less than 30) were targeted, and those who did not meet any of the items in the “exclusion criteria” below were recruited. 200 subjects were included in this study.
Exclusion criteria
・ Obesity, hyperlipidemia, those who use / take medications that may affect lipid metabolism ・ severe liver disorder, cardiovascular disorder, respiratory disorder, endocrine disorder, metabolic disorder, food allergy disorder Who are suffering from obesity, who have obesity, hyperlipidemia, who can not stop the intake of health foods and supplements that may affect lipid metabolism, drug dependence, and a history of alcoholism or medical history Person, person who can not abstain from 2 days before the inspection day (Visit 2, 3, 6, 8, 10, 11) Person who has metal in the CT scan measurement site by surgery etc. Heart pacemaker, implantable defibrillator Person who has been diagnosed ・ who has been diagnosed with phenylketonuria or hyperphenylalaninemia ・ who has been diagnosed with familial hyperlipidemia ・ who is pregnant or lactating, or who is testing Person who wants pregnancy during period Those who have an irregular diet or life cycle such as late-night work, those who are participating in trials of using / taking medications / tests for taking / testing on other foods, taking medicines, those who are willing to participate・ Afflicted with claustrophobia ・ Others, who are judged as unsuitable as study participants at the discretion of the investigator

The subject background is summarized in Table 1 below.

Study Design This study was a double blind randomized parallel parallel comparison study.

Test food
Test food to be ingested in A-mix group: 500 mL of plastic bottle beverage containing 1500 mg of A-mix Control food ingested to placebo group: plastic bottle beverage without A-mix

Evaluation items Three-month changes in blood pressure were evaluated.

Study schedule The number of visits to the test site during the test was 11 times in total (1st: study participation briefing session, 2nd: screening test, 3rd: pre-intake test, 4th: first face-to-face exercise classroom, 5 The second: the second face-to-face exercise classroom, the sixth: the first month examination, the seventh: the third face-to-face exercise school, the eighth: the second month examination, the ninth: the fourth face-to-face exercise classroom, the tenth: three months Eye inspection, 11th: Post-hoc inspection).

  Specifically, 200 subjects were selected and selected at the first to third visits, and exercise and food instruction were given once a month for 4 to 10 third months. In addition, the test food was ingested once a day during these three months. In the exercise instruction, while enlightening the increase in the number of steps more than 1000 steps a day, I did the practice of stretching and muscle training. In the food guidance, we provided the "Food Balance Guide" of the Ministry of Agriculture, Forestry and Fisheries, and instructed them to keep a balanced diet in mind.

  The blood parameters of liver function (AST, ALP, γ-GTP) were examined a total of 5 times every 4 weeks (0, 4, 8, 12, 16 weeks). At the time of blood test, we also carried out a health check by urine test, interviews, etc. and also checked the amount of food and the amount of activity (amount of exercise).

Statistical analysis Basic statistics (mean and standard deviation) at 0, 4, 8, 12 weeks were calculated. The comparison was performed by comparing the 0 week and each week by a paired t-test.

Results Changes in AST are shown in FIG. 1, changes in ALP are shown in FIG. 2, and changes in γ-GTP are shown in FIG. Here, # indicates that there is a significant difference (in-group comparison, corresponding t-test) as compared to p <0.05 and 0 week. In addition, the number of analysis subjects is at week 0: 200 (A-mix 100-placebo 100), at 4 weeks: 199 (A-mix 100-placebo 99), at 8 weeks: 199 (A-mix 99-placebo) 100), 12 weeks: 198 (A-mix 98-placebo 100).

  As for AST, as shown in FIG. 1, the A-mix group showed significantly lower values at 4 weeks and 12 weeks after ingestion than at 0 week. On the other hand, although not shown, the placebo group showed a significantly lower value than week 0 only after 12 weeks after intake.

  With regard to ALP, the A-mix group showed significantly lower values at 8 and 12 weeks after ingestion than at 0 week. On the other hand, although not shown, the placebo group showed a significantly lower value than week 0 only after 12 weeks after intake.

  As for γ-GTP, the A-mix group showed significantly lower values at 4, 8, 12 weeks after ingestion than at 0 week. On the other hand, although not shown, the placebo group showed a significantly lower value than week 0 only after 12 weeks after intake.

  Thus, it was revealed that intake of the composition of the present invention significantly improves liver function when used in combination with awareness raising of physical activity as compared with placebo.

  According to the present invention, it is possible to effectively improve liver function and develop agents, foods, beverages, medicines and the like for improvement of liver function which can be expected to improve liver function even with low intensity exercise load. .

Claims (7)

  A composition for improving liver function comprising arginine, alanine and phenylalanine as active ingredients, wherein the total number of moles of all amino acids in the composition is 100 moles, and the mole of arginine, alanine and phenylalanine The composition, wherein the sum of the numbers is at least 60 moles.   The composition according to claim 1, wherein the molar ratio of arginine, alanine and phenylalanine is 5.0 to 90.0: 5.0 to 90.0: 5.0 to 90.0.   The composition according to claim 2, wherein the molar ratio of arginine, alanine and phenylalanine is 10.0 to 30.0: 20.0 to 60.0: 10.0 to 70.0.   The composition according to any one of claims 1 to 3, wherein the total number of moles of arginine, alanine and phenylalanine is 90 to 100 moles when the total number of moles of all amino acids is 100 moles.   The composition according to any one of claims 1 to 4, for reducing at least one blood parameter selected from AST, ALP and γ-GTP.   Food-drinks which are made to contain the composition as described in any one of Claims 1-5.   The food and drink according to claim 6, which is any one form selected from the group consisting of a beverage, granules, powder and liquid food.